anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Clinical significance == Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD).
DPP-4 inhibitors usually have an electrophilic group that can interact with the hydroxyl of the catalytic serine in the active binding site (Figure 3). Frequently that group is a nitrile group but can also be boronic acid or diphenyl phosphonate. This electrophilic group can bind to the imidate complex with covalent bonds and slow, tight-binding kinetics but this group is also responsible for stability issues due to reactions with the free amino group of the P2-amino acid. Therefore, inhibitors without the electrophilic group have also been developed, but these molecules have shown toxicity due to affinity to other dipeptidyl peptidases, e.g. DPP-2, DPP-8 and DPP-9. DPP-4 inhibitors span diverse structural types. In 2007 few of the most potent compounds contain a proline mimetic cyanopyrrolidine P1 group. This group enhances the potency, probably due to a transient covalent trapping of the nitrile group by the active site Ser630 hydroxyl, leading to delayed dissociation and slow tight binding of certain inhibitors. When these potency enhancements were achieved, some chemical stability issues were noted and more advanced molecules had to be made. To avoid these stability issues, the possibility to exclude the nitrile group was investigated. Amino acids with aryl or polar side chains did not show appreciable DPP-4 inhibition and in fact, all compounds without the nitrile group in this research suffered a 20 to 50-fold loss of potency corresponding to the compounds containing the nitrile group.
place the five S American sections, Andinium, Leptidium, Tridens, Rubellium and Chilenium at the base of the phylogenetic tree, in that order. These are followed by the single Australian section, Erpetion, as sister group to Chilenium, the northern hemisphere sections and finally the single African section, V. abyssinica. These sections are morphologically, chromosomally, and geographically distinct.
Decoupling the enzymatic reaction and the image capture allows for optimal throughput and theoretically unlimited sequencing capacity. With an optimal configuration, the ultimately reachable instrument throughput is thus dictated solely by the analog-to-digital conversion rate of the camera, multiplied by the number of cameras and divided by the number of pixels per DNA colony required for visualizing them optimally (approximately 10 pixels/colony). In 2012, with cameras operating at more than 10 MHz A/D conversion rates and available optics, fluidics and enzymatics, throughput can be multiples of 1 million nucleotides/second, corresponding roughly to 1 human genome equivalent at 1x coverage per hour per instrument, and 1 human genome re-sequenced (at approx. 30x) per day per instrument (equipped with a single camera).
Sources: en.wikipedia.org
=== Former hospitals === Former UPMC hospitals include UPMC Sunbury in Sunbury, Pennsylvania (2017–2020) which was closed and services integrated into other nearby facilities; UPMC Beacon Hospital in Dublin, Ireland (2009 to 2014) which was acquired by Irish businessman Denis O'Brien; UPMC Braddock in Braddock, Pennsylvania (1996 to 2010) which was closed; UPMC South Side hospital in Pittsburgh (1996 to 2009) which was merged with UPMC Mercy and converted into UPMC Mercy South Side Outpatient Center; UPMC Lee Regional in Johnstown, Pennsylvania (1998 to 2005) which was sold to Conemaugh Health System; and UPMC Beaver Valley in Aliquippa, Pennsylvania (1996 to 2001) which was transferred back to its community board and subsequently closed. UPMC Pinnacle Lancaster, formerly St. Joseph's hospital in Lancaster, Pennsylvania, closed on February 28, 2019, and its services were consolidated into UPMC Pinnacle Lititz.
=== Further reading === Philip J. Kocieński: Protecting Groups, 1st ed., Georg Thieme Verlag, Stuttgart 1994, ISBN 3-13-135601-4. Peter G.M. Wuts, Theodora W. Greene: Green's Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons Inc., Hoboken, New Jersey, ISBN 0-471-69754-0. Michael Schelhaas, Herbert Waldmann: "Schutzgruppenstrategien in der organischen Synthese", in: Angewandte Chemie, 1996, 103, pp. 2192–2219; doi:10.1002/ange.19961081805 (in German). Krzysztof Jarowicki, Philip Kocieński: "Protecting groups", in: J. Chem. Soc., Perkin Trans. 1, 1998, pp. 4005–4037; doi:10.1039/A803688H.
== Evolution == Glycine is proposed to be defined by early genetic codes. For example, low complexity regions (in proteins), that may resemble the proto-peptides of the early genetic code are highly enriched in glycine.
Sources: en.wikipedia.org
Sam Chun Dang Pharm Co., Ltd. (Korean: 삼천당제약; Hanja: 三千堂製藥; RR: Samcheondang jeyak), commonly abbreviated as SCD, is a South Korean pharmaceutical company engaged in the development, manufacturing, and sale of prescription medicines. Founded in 1943, the company is headquartered in Seocho-gu, Seoul, with manufacturing operations at the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. SCD is listed on the Korea Exchange (KRX: 000250). The company is best known for its ophthalmic products, which accounts for approximately half of its total revenues, and has attracted attention for its development of an aflibercept biosimilar (SCD411) and an oral semaglutide generic.
== Biology == Selenenic acids derived from selenocysteine are involved in cell signaling and certain enzymatic processes. The best known selenoenzyme, glutathione peroxidase (GPx), catalyzes the reduction of peroxides by glutathione (GSH). The selenenic acid intermediate (E-SeOH) is formed upon oxidation of the catalytically active selenol (E-SeH) by hydrogen peroxide. This selenenic acid derivative of the peroxidase then reacts with a thiol-containing cofactor (GSH) to generate the key intermediate selenenyl sulfide (E-SeSG). This intermediate is subsequently attacked by a second GSH to regenerate the selenol and the glutathione cofactor is released in its oxidized form, GSSG. The catalytic mechanism of GPx, involves selenol (R-SeH), selenenyl sulfide (R1-SeS-R2), and selenenic acid intermediates.
Chymotrypsins (EC 3.4.21.1, including enzymes called alpha-chymotrypsin, chymotrypsin A, and chymotrypsin B) are digestive enzymes that form a component of pancreatic juice acting in the duodenum, where they perform proteolysis, the breakdown of proteins and polypeptides. In humans, the corresponding enzymes are encoded by the genes CTRB1 and CTRB2. The related enzyme chymotrypsin-C (EC 3.4.21.2) acts similarly, but with some differences including a preference for cutting leucine over phenylalanine bonds. Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. It is activated in the presence of trypsin. The hydrophobic and shape complementarity between the peptide substrate P1 side chain and the enzyme S1 binding cavity accounts for the substrate specificity of this enzyme. Chymotrypsin also hydrolyzes other amide bonds in peptides at slower rates, particularly those containing leucine at the P1 position. Structurally, it is the archetypal structure for its superfamily, the PA clan of proteases.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.